Our Network
The Global Asthma Network currently has 387 centres in 138 countries and aims to have centres in all countries in the world. The Global Asthma Network is currently taking expressions of interest from new centres. We are particularly interested in centres from these countries. Click here to see the map.
Clinical standards for asthma in September's IJTLD
New clinical standards for asthma have been published in the September issue of the The International Journal of Tuberculosis and Lung Disease. There was great participation from GAN collaborators in the Delphi process that underpinned the development of these standards, and many are included as authors. These first consensus-based clinical standards for asthma management in LMICs are intended to help clinicians provide the most effective care for people in resource-limited settings.
GAN Eczema Paper published with Editorial
The GAN Eczema Time Trends paper as been selected for the editorial in the March edition of Clinical and Experimental Allergy. These new global time trends provide important data for the scope and direction of eczema strategy.
GAN Asthma Management Paper published with Editorial and Podcast
The GAN Asthma Management paper has been published in the February edition of The Lancet Global Health. This editorial highlights once again the burden of asthma globally and the lack of progress in reducing the worldwide burden of asthma. Additionally the journal has interviewed the authors in a podcast discussing the findings of this new paper.
Global Asthma Report 2022
The Global Asthma Report 2022 was launched on 10 November 2022 at the Union’s World Conference on Lung Health, by Innes Asher. The slides used in her presentation can be downloaded here. This state of the art Report is 102 pages (18 chapters) written by 97 authors from 31 countries around the world.
World Lung Day 2022: Lung Health for All
On World Lung Day, 25 September 2022, the Forum of International Respiratory Societies (FIRS) calls on governments worldwide to address stark global inequalities in respiratory health.
The COVID-19 pandemic may have subsided, but its impact highlights a global lung health crisis that has not gone away.
Read moreLatest GAN Newsletter available
The September 2022 GAN Newsletter is now available on the website. This is our 10 year anniversary Newsletter and includes contributions from our members towards this occasion. In addition, Included in the newsletter are articles on GAN Phase I update, New GAN publications, a FIRS Lung Health facts sheet for World Lung Day, Global Asthma Report update, GAN Centres update and GAN & GAR website usage view newsletter
GAN Asthma Papers published with Editorial
The GAN Asthma Child and adult worldmap papers have been published in the September edition of the European Respiratory Journal. This editorial highlights once again the burden of asthma globally and the importance of monitoring this disease.
GAN Rhinitis Paper selected for Editorial
The GAN Rhinitis Time Trends paper as been selected as Editors choice in the February edition of Paediatric Allergy and Immunology. These new global time trends provide important data for the scope and direction of rhinitis strategy.
Asthma Time Trends
First publication on asthma prevalence from the GAN Phase I published with open access in The Lancet. These new global asthma time trends provide important data for the scope and direction of asthma strategy. Read more
Global Asthma Network Symposium 2024
Improving access to affordable inhaled medicines for all
22 January 2024, Auckland, New Zealand
This exciting all day event will include presentations and discussion of GAN Phase I papers and invited perspectives from asthma experts from New Zealand, the Global Initiative for Asthma (GINA), World Health Organization and others
This symposium builds on GAN’s state of the art Global Asthma Report 2022 - www.globalasthmareport.org
Register Now
Funding and development partners
The Global Asthma Network received major funding from The International Union Against Tuberculosis and Lung Disease (The Union) from 2012-2015. It is also generously supported by funding from the following organisations:
- Global Asthma and Allergy Patient Platform
- IMPALA
- We thank the NIHR Global Health Research Unit on Lung Health and TB in Africa at LSTM - “IMPALA” for helping to make this work possible. In relation to IMPALA (project reference 16/136/35) specifically: IMPALA was funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care.
- OM Pharma
- Australia
- Asthma Australia
- Woolcock Institute of Medical Research
- France
- Aix Marseille University
- Georgia
- Center of Allergy & Immunology, Tbilisi
- Latvia
- Riga Stradins University
- New Zealand
- The Asthma and Respiratory Foundation of New Zealand
- Auckland Asthma Charitable Trust
- Boehringer Ingelheim
- University of Auckland
- AstraZeneca
- Spain
- University of Murcia
- Valencia University
- Sultanate of Oman
- The Oman Respiratory Society
- United Kingdom
- The London School of Hygiene and Tropical Medicine
- St Georges University of London
- UK Medical Research Council
Funders of GAN Phase I Centres
Individual centres involved in GAN Phase I data collection were funded by the following organisations:
- Argentina, San Francisco
- Funded by Dr Héctor Badellino
- Brazil, Uruguaiana
- Funded by Dr Marilyn Urrutia Pereira
- Cameroon, Yaounde
- Funded by Elvis Ndikum (95%) and from family, friends (5%)
- Costa Rica
- Partially funded by an unrestricted grant from Astra Zeneca for logistic purposes
- India; Bikaner, Chandigarh, Jaipur, Kolkata, Kottayam, Lucknow, Mysuru, New Delhi, Pune
- GAN Phase I was undertaken by Asthma Bhawan in India which was supported by Cipla foundation.
- Iran, Karaj
- Alborz University of medical Sciences
- Kosovo, Gjakova
- Municipality of Gjakova and the Directorate for Health and Education
- Mexico, all centres
- Astra Zeneca and COMPEDIA (Colegio Mexicano de Pediatras Especialistas en Inmunologia Clinica y Alergia) educational grants
- Mexico, Puerto Vallarta
- Centro Universitario de la Costa, Universidad de Guadalajara
- New Zealand, Auckland
- Auckland Asthma Charitable Trust
- Nicaragua. Managua
- Partially funded by an unrestricted grant from Astra Zeneca for logistic purposes
- Nigeria, Ibadan
- Funded by National Institute for Health Research (NIHR) (IMPALA, grant reference 16/136/35) using UK aid from the UK Government to support global health research
- Poland, Katowice
- Funded by the Medical University of Silesia
- South Africa, Cape Town
- Funded by the South African Medical Research Council and by the Allergy Society of South Africa for Heather Zar
- Spain, Cartagena, Bilbao, Pamplona
- Funded by Instituto de Salud Carlos III
- Spain, Cantabria
- Funded by Instituto de Investigación Sanitaria Valdecilla (IDIVAL) de Cantabria PRIMVAL 17/01 y 18/01,
- Spain, Salamanca
- Funded by Gerencia Regional de Salud de la Junta de Castilla y León Sociedad Española de Inmunología Clínica, Alergología y Asma Pediátrica,
- Spain, A Coruña
- Funded by María José Jove foundation.
- Sri Lanka; Anuradhapura, Peradeniya
- University of Peradeniya, Peradeniya, Sri Lanka
- Syria; Damascus, Lattakia
- Damascus: Syrian Private University
- Lattakia: Lattakia Medical National Syndicate